Hormone receptor-positive metastatic breast cancer management relies heavily on targeted cell cycle control. However, both acquired and de novo CDK4/6 inhibitor resistance continue to hinder long-term treatment success. Consequently, identifying predictive biomarkers and overcoming therapy failure remain urgent clinical priorities in modern oncology.

Mechanisms Driving CDK4/6 Inhibitor Resistance

Combinations of endocrine therapy and CDK4/6 inhibitors represent the global standard for advanced estrogen receptor-positive breast cancer. Agents like abemaciclib and palbociclib halt cell cycle progression through G1 arrest by blocking retinoblastoma protein phosphorylation. Nevertheless, a substantial proportion of patients eventually progress due to adaptive drug tolerance. Clinicians currently face significant hurdles because reliable predictive biomarkers for patient selection do not exist in daily practice.

To investigate these resistance drivers, investigators generated drug-tolerant persisters across multiple estrogen receptor-positive breast cancer cell lines. Interestingly, these persistent cells survived prolonged inhibitor exposure while displaying marked G1 arrest and cellular senescence. Rather than acquiring permanent genetic mutations, these cells frequently reprogram their transcriptomic machinery. Therefore, characterizing the gene expression shifts in drug-tolerant persister models provides essential insights into early escape pathways. By understanding these non-genomic adaptations, oncologists can better anticipate treatment failure and develop rational therapeutic combinations.

Identification of GPNMB in Drug-Tolerant Persisters

Researchers performed comprehensive transcriptomic profiling on drug-tolerant persister cell lines using Clariom D assays. This high-throughput screen identified 154 differentially expressed genes consistently linked to therapy resistance across cell models. Notably, investigators compared these candidate genes with published transcriptomic data from the randomized phase III PEARL clinical trial. This trial evaluated palbociclib plus endocrine therapy versus capecitabine in endocrine-resistant metastatic breast cancer.

Remarkably, glycoprotein nonmetastatic melanoma protein B, commonly designated as GPNMB, emerged as a strongly upregulated candidate across both experimental datasets. Baseline estrogen receptor-positive cells demonstrated minimal GPNMB expression, whereas drug-tolerant cells exhibited robust overexpression. Because GPNMB was independently enriched in clinical trial specimens, researchers confirmed its direct relevance to human disease. Consequently, GPNMB shifted from an uncharacterized transcript to a leading biomarker candidate for cyclin-dependent kinase inhibitor resistance.

Integrin Signaling and Tumor Progression

To prove whether GPNMB actively causes therapeutic failure, scientists engineered stable GPNMB overexpression in sensitive breast cancer lines. Strikingly, GPNMB overexpression completely abolished the growth-inhibitory effects of abemaciclib and palbociclib. In addition, these modified cells demonstrated increased migratory capacity and invasiveness in vitro. Xenograft models further established that GPNMB-overexpressing tumors progressed much faster than control tumors.

Across all treatment arms, GPNMB-overexpressing xenografts failed to respond to CDK4/6 blockade. Mechanistically, GPNMB overexpression markedly increased the expression of cell adhesion integrins, specifically integrin alpha 5 (ITGA5) and integrin beta 1 (ITGB1). Furthermore, this integrin upregulation activated key downstream survival kinases, as evidenced by elevated phosphorylated AKT (Ser473) and phosphorylated ERK 1/2 (Thr202/204). Thus, GPNMB triggers an alternative pro-survival signaling circuit that circumvents cell cycle inhibition. This bypass mechanism allows malignant cells to proliferate vigorously despite therapeutic drug levels.

Antibody-Drug Conjugates Overcoming Resistance

Because GPNMB is a cell-surface transmembrane glycoprotein, it offers an accessible target for antibody-directed therapeutics. Therefore, investigators evaluated whether targeting GPNMB could eliminate resistant breast cancer cells. Specifically, they utilized glembatumumab vedotin, an antibody-drug conjugate comprising an anti-GPNMB monoclonal antibody coupled to the potent microtubule inhibitor monomethyl auristatin E.

When administered as a single agent, glembatumumab vedotin potently decreased the viability of GPNMB-overexpressing cells. Even more impressively, combining glembatumumab vedotin with abemaciclib produced profound synergistic antitumor activity. Although abemaciclib alone could not inhibit resistant tumors, it enhanced the cytotoxic efficacy of the antibody-drug conjugate. Consequently, this targeted combination successfully overcame acquired resistance in preclinical models. This finding highlights a transformative approach: converting an adverse resistance biomarker into a direct therapeutic target for antibody-drug conjugates.

Clinical Implications for Future Practice

These findings provide actionable clinical insights for treating hormone receptor-positive metastatic breast cancer. Currently, oncologists lack predictive tools to guide sequencing when patients demonstrate intrinsic or rapid resistance to CDK4/6 inhibitors. If validated clinically, measuring baseline GPNMB expression through biopsy or liquid biopsy could identify patients unlikely to benefit from standard CDK4/6 inhibitor combinations.

Moreover, these insights create compelling rationale for novel clinical trials. Although glembatumumab vedotin previously showed mixed results in unselected metastatic populations, biomarker enrichment could yield superior clinical outcomes. Testing this conjugate specifically in GPNMB-positive, CDK4/6 inhibitor-resistant cohorts might salvage disease control. Additionally, dual targeting of downstream AKT and ERK pathways represents another promising therapeutic avenue. Ultimately, translating GPNMB detection into routine oncology practice could refine treatment sequencing and improve survival outcomes.

Frequently Asked Questions

How does GPNMB overexpression promote resistance to CDK4/6 inhibitors?

GPNMB functions as a transmembrane glycoprotein that significantly upregulates integrin alpha 5 and integrin beta 1 on breast cancer cells. Consequently, this integrin elevation activates downstream survival cascades, notably the AKT and ERK signaling pathways. Because these hyperactive kinases provide robust pro-survival signals, cancer cells successfully bypass the G1 cell cycle arrest normally produced by CDK4/6 inhibitors like palbociclib and abemaciclib.

Can clinicians currently test for GPNMB expression in routine practice?

Currently, routine clinical testing for GPNMB expression is not standardized in daily oncology practice. However, researchers regularly evaluate GPNMB levels using transcriptomic analysis and immunohistochemistry within clinical trial settings. As further validation studies confirm its predictive accuracy, specialized molecular assays may enter clinical laboratories to identify breast cancer patients who are unlikely to benefit from initial CDK4/6 inhibitor regimens.

What therapeutic strategies show promise against GPNMB-driven breast cancer?

Preclinical studies indicate that the antibody-drug conjugate glembatumumab vedotin effectively targets GPNMB-overexpressing cancer cells. Furthermore, combining this targeted agent with abemaciclib demonstrates powerful synergistic cytotoxicity against resistant breast tumors. Additionally, researchers are investigating combinatorial approaches that block downstream AKT and ERK signaling cascades to prevent cancer cells from circumventing CDK4/6 inhibitor-mediated growth suppression.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice or relied upon for any diagnosis or treatment. Healthcare professionals must exercise independent clinical judgment, and patients should always consult their physician. Refer to the latest local and national guidelines for clinical practice.

References

1. Gu Y et al. Glycoprotein nonmetastatic melanoma protein B overexpression-a marker of resistance to cyclin-dependent kinase 4 and 6 inhibitors. J Natl Cancer Inst. 2026 Nov 02. doi: undefined. PMID: 42970014.
2. Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol. 2021;32(4):488-499.
3. Wander SA, Cohen O, Gong X, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174-1193.